Background and Purpose-Although statin use has been linked to the stabilization of systemic atherosclerosis, its effect on symptomatic intracranial atherosclerotic plaques has yet to be explored. We hypothesized that premorbid statin use is associated with plaque instability in intracranial arteries and may lead to differential patterns (size and distribution) of ischemic lesions in patients with acute intracranial atherosclerotic stroke. Methods-One hundred and thirty-six patients with acute infarcts caused by intracranial atherosclerotic stroke underwent high-resolution magnetic resonance imaging. Patients were categorized into 3 groups based on their premorbid statin use: nonuser, low-dose user, and high-dose user, according to the 2013 American College of Cardiology/American Heart Association guidelines on blood cholesterol. Symptomatic lesions in intracranial arteries were analyzed using highresolution magnetic resonance imaging for vascular morphology (degree of stenosis, remodeling index, and wall index) and plaque activation (pattern and volume of enhancement). The cortical distribution and volume of ischemic brain lesions were measured using diffusion-weighted imaging. Results-Among the enrolled patients, 38 (27.94%) were taking statins before the index stroke (22 low-dose statins and 16 high-dose statins). The degree of stenosis, remodeling index, and wall index did not differ between the 3 groups. However, the volume of plaque enhancement was significantly lower in statin users (nonuser, 33.26±40.72; low-dose user, 13.15±17.53; high-dose user, 3.13±5.26; P=0.002). Premorbid statin use was associated with a higher prevalence of nonembolic stroke and a decrease in large cortical infarcts (P=0.012). 
T he lowering of cholesterol with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) has shown protective effects against coronary, carotid, and intracranial artery atherosclerosis. [1] [2] [3] Pleiotropic effects on atherosclerotic plaque stabilization in coronary and extracranial arteries have also been reported. 4, 5 Results from clinical trials support a significant decrease in vascular events in groups of patients treated with statins. 6 The previous use of statins has been associated with preserved microvascular integrity, reduced incidence of plaque rupture, and a thicker fibrous cap in coronary plaques. 7, 8 However, a paucity of data currently exists on the effects of previous statin use in patients with symptomatic intracranial atherosclerosis. Ischemic stroke caused by carotid artery stenosis mostly results from artery-to-artery embolism and rarely from hemodynamic insufficiency. Coronary artery plaque can cause acute myocardial infarction by thrombus formation at the site of plaque rupture. However, intracranial atherosclerotic stroke (ICAS) can be caused by 2 pathophysiological mechanisms with discrete clinical and radiological characteristics: by subcortical infarcts caused by parent arterial disease occluding the orifice of a perforator and by coronary-type plaque rupture,
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which is characterized by multiple ischemic lesions caused by emboli from ruptured plaques in the proximal artery. 9, 10 Therefore, the effect of statin use in ICAS may differ from myocardial infarction and ischemic stroke caused by extracranial arteries, possibly modifying the clinical phenotype.
In this study, we hypothesized that premorbid statin use is associated with differential characteristics of intracranial atherosclerotic plaque, that is the degree of stenosis, extent of vascular remodeling, and plaque activation, which could lead to different mechanisms of ICAS. Thus, we gathered information on statin use before the index stroke and evaluated the plaque characteristics of symptomatic intracranial arteries using high-resolution magnetic resonance imaging (HR-MRI) in ICAS. Furthermore, ischemic lesions on diffusion-weighted imaging (DWI) and initial stroke severity were assessed with respect to previous statin use.
Materials and Methods

Study Population
This study relied on the screening of participants of the Intensive Statin Treatment in Acute Ischemic Stroke Patients With Intracranial Atherosclerosis (STAMINA-MRI) trial. The STAMINA-MRI study is an ongoing trial evaluating the efficacy of high-dose statin treatment in the stabilization of intracranial atherosclerotic plaque (NCT02458755). Between February 2012 and September 2015, patients were enrolled in this study if they had been admitted to a university medical center for the treatment of acute ischemic stroke within 7 days of symptom onset. Among the subjects, the study included for analysis those who were diagnosed with ICAS (any degree of stenosis of relevant intracranial vessels, the M1 portion of the middle cerebral artery or the basilar artery) and had undergone HR-MRI during hospitalization. Patients were excluded if they had potential sources of cardioaortic embolism based on the Stop Stroke Study Trial of Org 10172 in Acute Stroke Treatment (SSS-TOAST), 11 extracranial atherosclerosis with significant (≥50%) stenosis in relevant extracranial arteries, other stroke mechanisms (coagulopathy, moyamoya disease, dissection, and others), or incomplete evaluations. We further excluded patients who had a previous history of stroke, incomplete history of previous medication, or contraindications for HR-MRI; were unable to cooperate because of unstable medical conditions or severe neurological deficits; or had poor-quality imaging data (eg, motion artifacts). Local institutional review boards approved this study. All participants or their guardians provided informed consent to participate in the study. Patient selection is shown in Figure 1 .
Stroke Work-Ups
Clinical information, including age, sex, vascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia, history of coronary artery disease, and smoking), initial stroke severity, and 90-day modified Rankin Scale score were systematically acquired. All patients underwent standardized diagnostic tests that included blood tests (including total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein [LDL] cholesterol, lipoproteinassociated phospholipase A 2 [Lp-PLA 2 ], high-sensitivity C-reactive protein, and erythrocyte sedimentation rate) and cardiac work-ups (electrocardiography, echocardiography, or ≥24-hour cardiac telemetry). All patients underwent brain MRI with DWI and magnetic resonance angiography (cervical gadolinium-enhanced magnetic resonance angiography and 3-dimensional time-of-flight magnetic resonance angiography of the circle of Willis).
The type and dose of statin were recorded at the time of admission, and the patients were categorized by their statin dose based on its LDL-lowering potency, according to the 2013 American College of Cardiology/American Heart Association blood cholesterol guidelines, as low-dose users taking a <40-mg atorvastatin-equivalent dose or as high-dose users taking a ≥40-mg atorvastatin-equivalent dose. 12, 13 Premorbid statin use was defined as regular statin medication for more than a month before the index stroke. Statin treatment was continued during acute period in patients taking statins before stroke. Adjustment of statin dose was made by treating physician according to 2013 American College of Cardiology/American Heart Association blood cholesterol guidelines. 13 The ischemic brain lesions were measured on DWI in terms of volume and distribution. The volume of the ischemic lesion was measured using the Medical Image Processing Analysis and Visualization (Center for Information Technology, National Institutes of Health, Bethesda, MD) program. We divided the patients into 3 infarct topography pattern groups based on the observed ischemic lesion(s): (1) deep-only pattern, (2) small cortical-only pattern, and (3) large cortical/cortical-deep pattern. 
High-Resolution MRI
HR-MRI was performed using a 3-T system (Achieva; Phillips Medical System, Best, the Netherlands) with a standard 8-channel head coil. The neuroradiologist (J.C.) selected the vessel and site of evaluation based on clinical presentation and 3-dimensional time-offlight magnetic resonance angiography findings and chose the combination of acquisition orientations (axial only or axial and sagittal). Black-blood HR-MRI using the spatial presaturation technique was performed as follows: (1) axial and sagittal proton density (repetition time/echo time=2150/12.5 ms, echo train length=10, slice thickness=2 mm, flip angle=90°, matrix=280×280, field-of-view=14 cm, and number of excitations=2); (2) axial and sagittal T2-weighted images (repetition time/echo time=2150/100 ms, echo train length=10, slice thickness=2 mm, flip angle=90°, matrix=280×280, field-of-view=14 cm, and number of excitations=2); (3) sagittal T1 fluid-attenuated inversion recovery, pre and post contrast (repetition time/echo time=2100/10 ms, echo train length=6, slice thickness=2 mm, flip angle=90°, matrix=280×280, field-of-view=14 cm, number of excitations=2); and (4) axial postcontrast 3-dimensional T1-weighted volumetric isotropic turbo spin echo acquisition (repetition time/echo time=350/20 ms, turbo spin echo factor=25, 0.5 mm isotropic voxel, flip angle=90°, matrix=360×360, field-of-view=18 cm, and number of excitations=2).
The lumen and outer vessel contours were traced manually on T2 proton density-weighted images using the Medical Image Processing Analysis and Visualization program. The lumen area and vessel area were automatically calculated after tracing by the program. The wall area was regarded as the difference between the areas of the vessel and lumen (ie, wall area=vessel area−lumen area). Normal vessels located contralateral or proximal to the stenotic portion were also assessed as reference values. The degree of stenosis was calculated as: (1-lumen area of stenotic lesion/reference lumen area)×100%. The remodeling index was the ratio of the vessel area at the stenotic lesion to that of the reference vessel. We defined the wall area index as the ratio between the wall area at the stenotic lesion and that of the reference wall. Precontrast and postcontrast T1 fluid-attenuated inversion recovery images were compared to determine the presence or absence of enhancement, enhancement pattern (concentric versus eccentric), and enhancement volume. 15 The enhancement volume was measured semiautomatically using a Medical Image Processing Analysis and Visualization program. When multiple plaques were detected in a symptomatic intracranial artery, a plaque causing the highest degree of stenosis was considered symptomatic and selected for analysis. Two neurologists (J.-W.C. and J.H.) interpreted the HR-MRI images. A third reader (M.J.L.) was invited to resolve any disagreements between the 2 interpreters. All quantitative data were remeasured 2 weeks later by a neurologist (J.-W.C.) to estimate intraobserver variability. The intraclass correlation coefficients for the measured HR-MRI parameters were examined for both interobserver and intraobserver agreement, and the final database was locked after achieving intraclass correlation coefficients >0.80. 
Statistical Analysis
Categorical variables were summarized according to frequencies and percentages, whereas continuous variables were expressed as mean±SD. We examined the differences in discrete variables between the groups using χ Table 1 . The morphological findings, including maximal degree of stenosis, remodeling index, and wall area index of symptomatic intracranial atherosclerotic plaques, did not differ according to premorbid statin use. Among the parameters of plaque activity, the proportion of patients with plaque enhancement decreased in statin users in a dose-dependent manner (nonuser, 80.6%; low-dose user, 68%; high-dose user, 43%; P=0.006). Enhancement volumes of atherosclerotic plaques were also lower in premorbid statin users (nonuser, 34.02±42.24; lowdose user, 13.59±17.84; high-dose user, 4.43±6.31; P=0.011).
However, the enhancement patterns did not differ among groups. In terms of infarct patterns, patients treated with statins before the index stroke were more likely to have a deep-only pattern and fewer large cortical/cortical-deep patterns (P=0.012). Details of the HR-MRI findings and infarct patterns by premorbid statin use are summarized in Table 2 . A further association was assessed between the enhancement volume of symptomatic atherosclerotic plaque and ischemic lesions on DWI (Figure 2 ). Patients were categorized into 4 groups-a group without enhancement and tertile groups of enhancement volumes by sample size. Infarct patterns differed significantly depending on the group for symptomatic intracranial artery enhancement (P<0.001). The proportion of deep-only pattern decreased and large cortical/cortical-deep patterns increased with increasing enhancement volumes.
To evaluate the effect of premorbid statin use and enhancement volume on initial stroke severity, the volume of the ischemic lesion and initial NIHSS scores were categorized and analyzed by groups (Figure 3 ). Neither premorbid statin use nor enhancement volume was significantly associated with the 2 indicators of initial stroke severity. Furthermore, premorbid Figure I in the online-only Data Supplement).
Discussion
The major findings of this study are as follows. Premorbid statin use was associated with less frequent plaque enhancement and lower enhancement volume, a marker of plaque instability. Both lower degree of plaque enhancement and previous statin use were associated with a higher frequency of nonembolic lesion pattern. This suggests that proper statin treatment could be helpful in preventing large cortical infarcts by stabilization of intracranial atherosclerotic plaque. Recent studies have revealed a protective effect of statins against vascular disease risk, including a reduction of systemic inflammation and improvement in endothelial dysfunction. [16] [17] [18] Furthermore, statins have been shown to exert many pleiotropic effects, [19] [20] [21] which could explain, at least in part, the greater reduction in cardiovascular risk with statin use than other LDL-lowering modalities. 22, 23 The ability of statins to stabilize the culprit lesions of atherosclerotic plaque and prevent them from rupturing has also been demonstrated in symptomatic coronary arteries [24] [25] [26] and extracranial carotid arteries. 27 In accordance with its effects on coronary and carotid arteries, premorbid statin treatment resulted in plaque stabilization in symptomatic intracranial atherosclerotic plaques in this study, represented by the decreased amount of intraplaque enhancement. Although the lipid core, fibrous component, and intraplaque hemorrhage in intracranial plaque cannot be sufficiently differentiated on HR-MRI, plaque enhancement has been reported to be associated with symptomatic plaque, neovascularization, or increased endothelial permeability. 15 On the basis of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial, current American Heart Association/American Stroke Association guidelines recommend high-intensity statin treatment for the treatment of ICAS. 28, 29 However, the superiority of high-intensity over low-intensity statin treatment for ICAS remains to be explored and is unlikely to be resolved by future prospective randomized trials. The results of this study provide supporting evidence for the recommendation. The STAMINA-MRI trial is currently investigating the plaque-stabilizing effects of high-intensity statin treatment using serial follow-up HR-MRI studies in patients with ICAS.
In this study, the proportion of ischemic strokes resulting from plaque rupture (with a large cortical or cortical-deep distribution of ischemic lesions) decreased among premorbid statin users. An association between HR-MRI findings of symptomatic intracranial artery lesions and subtypes of ICAS has previously been reported. 30 Patients with infarcts beyond the striatocapsular area (such as cortical infarction, regardless of the presence of deep subcortical infarcts) had a more severe degree of stenosis and a higher proportion of plaques showing enhancement. In this study, the degree of stenosis, remodeling index, and wall area index did not show a significant difference depending on statin use. On the basis of these findings, the authors speculate that a decrease in large cortical infarcts in premorbid statin users is associated with the 
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plaque-stabilization effects of statins rather than modifying vascular stenosis or remodeling. Because only patients with ICAS were included, this study could not determine whether statin treatment reduces the incidence of ischemic cerebrovascular events in patients with intracranial atherosclerosis. However, most high-dose statin users experience ischemic strokes in which lesions are restricted to deep cerebral structures. Hence, statin use may have a limited protective effect against branch occlusive disease. Further research needs to focus on developing preventive strategies for branch occlusive disease using treatments other than statins.
The effect of premorbid statin treatment on ischemic lesion pattern did not modulate initial stroke severity and 90-day functional outcome in the present study. Recent research emphasized the importance of lesion topography in initial stroke severity and long-term functional outcome rather than simple ischemic lesion volume or pattern. 31 Authors speculate that the discrepancy between ischemic lesion pattern and functional outcome in this study, at least in part, could be explain by the role of lesion topography on clinical outcome in patients with acute ischemic stroke.
Lp-PLA 2 , an enzyme produced by inflammatory cells that hydrolyzes oxidized phospholipids in LDL, was significantly associated with plaque enhancement volume in this study. Elevated levels of Lp-PLA 2 are a strong risk factor for coronary heart disease and stroke. 32 A reduction in Lp-PLA 2 levels with statin use has also been shown to significantly predict coronary heart disease events, independent of changes in LDL cholesterol. 33 However, the levels of the inflammatory biomarkers Lp-PLA 2 and high-sensitivity C-reactive protein were not significantly lower among previous statin users in this study. Future studies investigating the pathophysiological mechanisms involving diverse inflammatory biomarkers in ICAS may further clarify the plaque-stabilizing effects of stains.
Study Limitations
Several limitations of this study are acknowledged. First, despite a rise in the global use of statins for the primary prevention of stroke, a relatively small proportion of the patients with ICAS in this study were taking statins. Furthermore, the study only included Korean patients, who are known to have a higher prevalence of intracranial atherosclerosis than Westerners, and the generalizability of the study results may by guest on July 15, 2017 http://stroke.ahajournals.org/ Downloaded from therefore be limited. 34 Second, the importance of compliance in patients taking statin medications for determining stroke outcome has been reported. [35] [36] [37] However, because this study screened the participants of an ongoing trial, information on the exact duration and level of patient compliance with statin treatment was limited. A duration of more than a month for statin treatment was a qualifying indicator of premorbid statin use in this study. Third, by including only patients with stroke, previous statin users in this study could be a group of patients with statin failure and may not be adequate to represent general statin users. Fourth, by including patients with acute ischemic stroke within 7 days of symptom onset, time point of MRI examinations was not controlled in this study. The ischemic lesions on DWI and plaque enhancement on HR-MRI have been reported to vary over time. 38, 39 Finally, this was a single-center study with a limited sample size. During the 4 years of screening, data from only 136 patients were available for analysis. The limited number of subjects may not have provided sufficient comparison of ischemic lesion volume between the statin treatment groups.
Conclusions
Our data indicate that premorbid statin use modulates plaque enhancement in symptomatic intracranial atherosclerotic plaque and decreases the proportion of patients with large cortical infarctions. Our results emphasize the importance of appropriate prestroke statin treatment for decreasing large cortical infarcts in patients with intracranial atherosclerotic disease. In addition, cerebrovascular events also occurred in high-dose statin users, predominantly of the branch occlusive type, and their neurological severity was comparable with that of nonusers. Further research on the development of preventive strategies for branch occlusive stroke is warranted.
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